AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-243526643/approval-latuda-schizophrenia-adults.html" title="Facts and information about Approval: Latuda for schizophrenia in adults.(From the FDA)">Approval: Latuda for schizophrenia in adults.(From the FDA)</a>
Close
Set up an RSS feed that alerts you when new articles from The Brown University Child and Adolescent Psychopharmacology Update are available.
Frequently asked questions about RSS feeds
Approval: Latuda for schizophrenia in adults.(From the FDA)
On October 28 the FDA approved Latuda (lurasidone HCl) tablets for the treatment of adults with schizophrenia. Four 6-week controlled studies demonstrated the effectiveness and safety of Latuda. The most common adverse reactions reported in clinical trials were drowsiness; feelings of restlessness and the urge …
Related articles from newspapers, magazines, journals, and more
-
- Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of...
-
News wire article from: The America's Intelligence Wire
June 15, 2012
700+ words
-
- Sunovion Pharmaceuticals Canada Inc. Annonce Que Sante Canada a Approuve...
-
News wire article from: The America's Intelligence Wire
June 15, 2012
700+ words
-
- Dainippon Sumitomo Pharma Co Ltd (DSP) announces launch of Latuda (lurasidone...
-
News wire article from: Chemical Business Newsbase
February 3, 2011
700+ words
-
- Once-daily Latuda (lurasidone hydrochloride) now available in pharmacies...
-
News wire article from: Chemical Business Newsbase
February 3, 2011
700+ words
-
- FDA approves once-daily Latuda for the treatment of patients with schizophrenia.
-
News wire article from: Chemical Business Newsbase
October 28, 2010
700+ words
